215 related articles for article (PubMed ID: 9215839)
21. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
22. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
23. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
[TBL] [Abstract][Full Text] [Related]
24. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
25. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
26. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.
Piccaluga PP; Martinelli G; Malagola M; Rondoni M; Bianchini M; Vigna E; Bosi C; Gaitani S; Visani G; Baccarani M
Leuk Lymphoma; 2004 Apr; 45(4):731-3. PubMed ID: 15160947
[TBL] [Abstract][Full Text] [Related]
27. Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).
Galimberti S; Cervetti G; Cecconi N; Fazzi R; Pacini S; Guerrini F; Manetti C; Caracciolo F; Petrini M
J Immunother; 2004; 27(5):389-93. PubMed ID: 15314547
[TBL] [Abstract][Full Text] [Related]
28. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
29. Campath-1H.
Sorokin P
Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
[TBL] [Abstract][Full Text] [Related]
30. In vivo 'purging' of residual disease in CLL with Campath-1H.
Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
[TBL] [Abstract][Full Text] [Related]
31. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
33. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
Heider U; Fleissner C; Zavrski I; Jakob C; Dietzel T; Eucker J; Ockenga J; Possinger K; Sezer O
Eur J Haematol; 2004 Jan; 72(1):64-6. PubMed ID: 14962266
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study.
Uppenkamp M; Engert A; Diehl V; Bunjes D; Huhn D; Brittinger G
Ann Hematol; 2002 Jan; 81(1):26-32. PubMed ID: 11807632
[TBL] [Abstract][Full Text] [Related]
35. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
36. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
37. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
Chaar BT; Petruska PJ
Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
[No Abstract] [Full Text] [Related]
38. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
40. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Döhner H; Ho AD; Thaler J; Stryckmans P; Sonneveld P; de Witte T; Lechner K; Lauria F; Bödewadt-Radzun S; Suciu S
J Natl Cancer Inst; 1993 Apr; 85(8):658-62. PubMed ID: 8468724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
